Published in Carcinogenesis on August 01, 1999
A SNP in a let-7 microRNA complementary site in the KRAS 3' untranslated region increases non-small cell lung cancer risk. Cancer Res (2008) 5.05
The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis. Br J Cancer (2005) 3.40
High resolution melting analysis for the rapid and sensitive detection of mutations in clinical samples: KRAS codon 12 and 13 mutations in non-small cell lung cancer. BMC Cancer (2006) 2.97
Pooled analysis of the prognostic and predictive effects of KRAS mutation status and KRAS mutation subtype in early-stage resected non-small-cell lung cancer in four trials of adjuvant chemotherapy. J Clin Oncol (2013) 1.66
Dual phosphoinositide 3-kinase/mammalian target of rapamycin blockade is an effective radiosensitizing strategy for the treatment of non-small cell lung cancer harboring K-RAS mutations. Cancer Res (2009) 1.64
Biomarkers in early-stage non-small-cell lung cancer: current concepts and future directions. J Thorac Oncol (2014) 1.56
Clinical relevance of KRAS in human cancers. J Biomed Biotechnol (2010) 1.34
Prognostic factors in stage III non-small cell lung cancer: a review of conventional, metabolic and new biological variables. Ther Adv Med Oncol (2011) 1.32
Linking molecular classification of hepatocellular carcinoma and personalized medicine: preliminary steps. Curr Opin Oncol (2008) 1.26
Detection of K-Ras mutations in tumour samples of patients with non-small cell lung cancer using PNA-mediated PCR clamping. Br J Cancer (2009) 1.11
Regression of drug-resistant lung cancer by the combination of rosiglitazone and carboplatin. Clin Cancer Res (2008) 1.09
Therapeutic targeting of human hepatocyte growth factor with a single neutralizing monoclonal antibody reduces lung tumorigenesis. Mol Cancer Ther (2008) 1.07
Sensitive and specific detection of K-ras mutations in colon tumors by short oligonucleotide mass analysis. Nucleic Acids Res (2004) 0.99
RAS Mutations and Oncogenesis: Not all RAS Mutations are Created Equally. Front Genet (2012) 0.99
Comparative analysis of dideoxy sequencing, the KRAS StripAssay and pyrosequencing for detection of KRAS mutation. World J Gastroenterol (2010) 0.96
Gene mutations in lung cancer: promising predictive factors for the success of molecular therapy. PLoS Med (2005) 0.94
Can microRNAs improve the management of lung cancer patients? A clinician's perspective. Theranostics (2013) 0.92
Wnt pathway activation predicts increased risk of tumor recurrence in patients with stage I nonsmall cell lung cancer. Ann Surg (2013) 0.90
CLEFMA-an anti-proliferative curcuminoid from structure-activity relationship studies on 3,5-bis(benzylidene)-4-piperidones. Bioorg Med Chem (2010) 0.89
Prognostic value of serum cytokeratin 19 fragments (Cyfra 21-1) in patients with non-small cell lung cancer. Sci Rep (2015) 0.84
Identification of candidate genes for lung cancer somatic mutation test kits. Genet Mol Biol (2013) 0.82
MET inhibition in lung cancer. Transl Lung Cancer Res (2013) 0.82
Prevalence of K-RAS Codons 12 and 13 Mutations in Locally Advanced Head and Neck Squamous Cell Carcinoma and Impact on Clinical Outcomes. Int J Otolaryngol (2013) 0.82
Selumetinib with and without erlotinib in KRAS mutant and KRAS wild-type advanced nonsmall-cell lung cancer. Ann Oncol (2016) 0.82
The curcuminoid CLEFMA selectively induces cell death in H441 lung adenocarcinoma cells via oxidative stress. Invest New Drugs (2010) 0.81
Parameters for individualizing systemic therapy in non-small cell lung cancer. Drug Resist Updat (2010) 0.78
KRAS Mutation Is a Significant Prognostic Factor in Early-stage Lung Adenocarcinoma. Am J Surg Pathol (2016) 0.78
Elderly former smoker with HRAS mutant non-small-cell lung cancer. J Thorac Oncol (2014) 0.77
Dinaciclib Induces Anaphase Catastrophe in Lung Cancer Cells via Inhibition of Cyclin-Dependent Kinases 1 and 2. Mol Cancer Ther (2016) 0.75
[Glandular papilloma of the right main bronchus. Detection of an exon 2 mutation of the KRAS gene (c.35G>A)]. Pathologe (2013) 0.75
Glucose catabolism in the rabbit VX2 tumor model for liver cancer: characterization and targeting hexokinase. Cancer Lett (2001) 2.11
Mitochondrial bound type II hexokinase: a key player in the growth and survival of many cancers and an ideal prospect for therapeutic intervention. Biochim Biophys Acta (2002) 1.79
Pleural mesothelioma in a lift mechanic. Br J Ind Med (1989) 1.67
First interim analysis of the GIDEON (Global Investigation of therapeutic decisions in hepatocellular carcinoma and of its treatment with sorafeNib) non-interventional study. Int J Clin Pract (2012) 1.65
Small cell carcinoma of the esophagus. The Massachusetts General Hospital experience, 1978 to 1993. Chest (1995) 1.55
Metastases in diffuse pleural mesothelioma: influence of histological type. Thorax (1987) 1.45
Treatment of recurrent high grade astrocytoma; results of a systematic review of 1,415 patients. Anticancer Res (1998) 1.45
GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib): second interim analysis. Int J Clin Pract (2013) 1.41
3-bromopyruvate: a new targeted antiglycolytic agent and a promise for cancer therapy. Curr Pharm Biotechnol (2010) 1.29
Percutaneous management of bile duct strictures and injuries associated with laparoscopic cholecystectomy: a decade of experience. J Am Coll Surg (2004) 1.21
Entrapment of J-tip guidewires by Venatech and stainless-steel Greenfield vena cava filters during central venous catheter placement: percutaneous management in four patients. Cardiovasc Intervent Radiol (1999) 1.20
Materials science. The hardest known oxide. Nature (2001) 1.03
Intravesical chemotherapy prophylaxis in primary superficial bladder cancer: a meta-analysis of 3703 patients from 11 randomized trials. J Clin Epidemiol (2000) 0.95
Diffuse meningeal thickening associated with pleural mesothelioma. Thorax (1990) 0.95
Percutaneous radiologic placement of peritoneal dialysis catheters: long-term results. J Vasc Interv Radiol (2000) 0.94
Ca2+ responses to interleukin 1 and tumor necrosis factor in cultured human skin fibroblasts. Possible implications for Reye syndrome. J Clin Invest (1991) 0.93
Cyclic AMP raises cytosolic Ca2+ and promotes Ca2+ influx in a clonal pancreatic beta-cell line (HIT T-15). FEBS Lett (1987) 0.92
Perineal application of cosmetic talc and risk of invasive epithelial ovarian cancer: a meta-analysis of 11,933 subjects from sixteen observational studies. Anticancer Res (2003) 0.91
T1-relaxation kinetics of extracellular, intracellular and intravascular MR contrast agents in normal and acutely reperfused infarcted myocardium using echo-planar MR imaging. Eur Radiol (2000) 0.89
Phase II study of chemoembolization with drug-eluting beads in patients with hepatic neuroendocrine metastases: high incidence of biliary injury. Cardiovasc Intervent Radiol (2012) 0.86
Genetic characteristics of prostate cancer. Cancer Epidemiol Biomarkers Prev (1995) 0.84
Prognostic significance of p53 mutations in non-small cell lung cancer: a meta-analysis of 829 cases from eight published studies. Cancer Lett (2000) 0.83
Serum prostate-specific antigen as a predictor of radiographic staging studies in newly diagnosed prostate cancer. Cancer Invest (1995) 0.82
Quantification of the extent of area at risk with fast contrast-enhanced magnetic resonance imaging in experimental coronary artery stenosis. Am Heart J (1996) 0.82
Planned preoperative radiation therapy in muscle invasive bladder cancer; results of a meta-analysis. Anticancer Res (1998) 0.82
Parental cancer and genetic predisposition in malignant pleural mesothelioma: a case-control study. Cancer Lett (1996) 0.82
Treatment and survival in diffuse malignant pleural mesothelioma; a study of 83 cases from the Massachusetts General Hospital. Anticancer Res (1996) 0.81
Behçet's disease complicated by pylephlebitis and hepatic abscesses. Clin Exp Rheumatol (2001) 0.80
New nonsurgical therapies in the treatment of hepatocellular carcinoma. Tech Vasc Interv Radiol (2001) 0.80
Multi-drug versus single agent chemotherapy for high grade astrocytoma; results of a meta-analysis. Anticancer Res (1999) 0.80
Management of hepatoma using cisplatin/epinephrine gel in patients awaiting orthotopic liver transplantation. Transplant Proc (2001) 0.79
Renal artery embolisation prior to radical nephrectomy for renal cell carcinoma: when, how and why? Br J Radiol (2010) 0.79
Coronary artery stenosis: detection with contrast-enhanced MR imaging in dogs. Radiology (1995) 0.78
Detection of acute myocardial ischemia using first-pass dynamics of MnDPDP on inversion recovery echoplanar imaging. J Magn Reson Imaging (1999) 0.78
Chemotherapy response rates in recurrent/progressive pediatric glioma; results of a systematic review. Anticancer Res (2000) 0.78
Single-specimen bile cytology: a prospective study of 80 patients with obstructive jaundice. J Vasc Interv Radiol (1998) 0.77
Identification of regional myocardial ischemia using contrast-enhanced dynamic magnetic resonance imaging in an experimental canine model of hemodynamically significant coronary arterial stenosis. Acad Radiol (1996) 0.76
Domestic asbestos exposure, lung fibre burden, and pleural mesothelioma in a housewife. Br J Ind Med (1989) 0.76
Distribution of intracellular, extracellular, and intravascular contrast media for magnetic resonance imaging in hearts subjected to reperfused myocardial infarction. Acad Radiol (1996) 0.76
Multislice measurement of first-pass transit of gadobenate dimeglumine in normal and ischemic myocardium in dogs. Acad Radiol (1995) 0.75
Pleural mesothelioma in a non-shipyard electrician. Br J Ind Med (1990) 0.75
Weight-based rt-PA thrombolysis protocol for acute native arterial and bypass graft occlusions. J Vasc Interv Radiol (2002) 0.75
Expanding and understanding risk factors for coronary heart disease. JAMA (1997) 0.75
Re: Current trends in prostate cancer diagnosis and staging among United States urologists. J Urol (1998) 0.75
Guidelines for radiographic studies in prostate cancer questioned. Oncology (Williston Park) (1997) 0.75
Pleural mesothelioma in a brake mechanic. Br J Ind Med (1989) 0.75
Cerebral metastases in pleural mesothelioma. Am J Clin Oncol (1990) 0.75
GPIIb-IIIa receptor inhibitors: what the interventional radiologist needs to know. Cardiovasc Intervent Radiol (2001) 0.75
Metastatic laryngeal carcinoma mimicking pleural mesothelioma. Respiration (1991) 0.75
Serum prostate-specific antigen as a predictor of staging abdominal/pelvic computed tomography in newly diagnosed prostate cancer. Abdom Imaging (1996) 0.75
Names for gadobenate dimeglumine. Radiology (1996) 0.75
The care of the mentally ill, and psychiatric nursing in Malta. Int J Nurs Stud (1973) 0.75
Balloon tamponade: a novel technique for visualizing and catheterizing the common bile duct after partial transection. J Vasc Interv Radiol (2001) 0.75
Vitamin supplement use in a hospital-based population. Eur J Cancer Prev (1992) 0.75